Advances in the treatment of coeliac disease: An immunopathogenic perspective

Nature Reviews Gastroenterology and Hepatology

Volumn 11, Issue 1, 2014, Pages 36-44

  Kaukinen, Katri ^a   Lindfors, Katri ^b   Mäki, Markku ^b  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE EP B2; CYTOKINE ANTIBODY; ENZYME INHIBITOR; GAMMA INTERFERON ANTIBODY; GLIADIN; GLIADIN ANTIBODY; GLUTEN; HLA DQ2 ANTIGEN; HLA DQ2 ANTIGEN BLOCKER; HLA DQ8 ANTIGEN; HLA DQ8 ANTIGEN BLOCKER; IMMUNOMODULATING AGENT; INTERLEUKIN 15; LARAZOTIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IL 15; PLACEBO; POLY(HYDROXYETHYLMETHACRYLATE CO STYRENESULFONATE); POLYSTYRENESULFONIC ACID; PROBIOTIC AGENT; PROLYL ENDOPEPTIDASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2 INHIBITOR; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

B LYMPHOCYTE; BACTERIAL STRAIN; BIFIDOBACTERIUM LONGUM INFANTIS; CELIAC DISEASE; CLINICAL EFFECTIVENESS; DIET SUPPLEMENTATION; DISEASE COURSE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENVIRONMENTAL FACTOR; ENZYME INHIBITION; ENZYME THERAPY; FOOD PROCESSING; FUNGAL STRAIN; GENETIC PREDISPOSITION; GLUTEN FREE DIET; HAPLOTYPE; HUMAN; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; INTESTINE EPITHELIUM; LACTOBACILLUS; LAMINA PROPRIA; LYMPHOCYTE HOMING; MICROBIAL ACTIVITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; T CELL DEPLETION; TARGET CELL DESTRUCTION; VACCINATION;

CELIAC DISEASE; DIET, GLUTEN-FREE; ENZYME THERAPY; HUMANS; PROBIOTICS;

EID: 84891741591     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2013.141     Document Type: Review

References (106)

1. Lohiniemi, S. Coeliac disease. Tricky to find, hard to treat, impossible to cure. Lancet 358 (Suppl.), S14 (2001)
2. Jabri, B. & Sollid, L. M. Tissue-mediated control of immunopathology in coeliac disease. Nat. Rev. Immunol. 9, 858-870 (2009)
3. Lohi, S. et al. Increasing prevalence of coeliac disease over time. Aliment. Pharmacol. Ther. 26, 1217-1225 (2007)
4. Kumar, P. J. in Changing Features of Coeliac Disease (eds Lohiniemi, S., Collin, P. & Mki, M.) 45-49 (The Finnish Coeliac Society, 1998)
5. Latorre, M. & Green, P. H. The role of corticosteroids in celiac disease. Dig. Dis. Sci. 57, 3039-3041 (2012)
6. Viljamaa, M. et al. Is coeliac disease screening in risk groups justified? A fourteen-year follow-up with special focus on compliance and quality of life. Aliment. Pharmacol. Ther. 22, 317-324 (2005)
7. Dewar, D. H. et al. Celiac disease: management of persistent symptoms in patients on a gluten-free diet. World J. Gastroenterol. 18, 1348-1356 (2012)
8. Shewry, P. R. & Halford, N. G. Cereal seed storage proteins: structures, properties and role in grain utilization. J. Exp. Bot. 53, 947-958 (2002)
9. van Overbeek, F. M. et al. The daily gluten intake in relatives of patients with coeliac disease compared with that of the general Dutch population. Eur. J. Gastroenterol. Hepatol. 9, 1097-1099 (1997)
10. Kasarda, D. D. in Coeliac Disease (eds Mki, M., Collin, P. & Visakorpi, J. K.) 195-212 (Coeliac Disease Study Group, 1997)
11. Hausch, F., Shan, L., Santiago, N. A., Gray, G. M. & Khosla, C. Intestinal digestive resistance of immunodominant gliadin peptides. Am. J. Physiol. Gastrointest. Liver Physiol. 283, G996-G1003 (2002)
12. Shan, L. et al. Structural basis for gluten intolerance in celiac sprue. Science 297, 2275-2279 (2002)
13. Spaenij-Dekking, L. et al. Natural variation in toxicity of wheat: potential for selection of nontoxic varieties for celiac disease patients. Gastroenterology 129, 797-806 (2005)
14. Di Cagno, R. et al. Sourdough bread made from wheat and nontoxic flours and started with selected lactobacilli is tolerated in celiac sprue patients. Appl. Environ. Microbiol. 70, 1088-1096 (2004)
15. Greco, L. et al. Safety for patients with celiac disease of baked goods made of wheat flour hydrolyzed during food processing. Clin. Gastroenterol. Hepatol. 9, 24-29 (2011)
16. Di Cagno, R. et al. Gluten-free sourdough wheat baked goods appear safe for young celiac patients: a pilot study. J. Pediatr. Gastroenterol. Nutr. 51, 777-783 (2010)
17. Stoven, S., Murray, J. A. & Marietta, E. Celiac disease: advances in treatment via gluten modification. Clin. Gastroenterol. Hepatol. 10, 859-862 (2012)
18. Gass, J. & Khosla, C. Prolyl endopeptidases. Cell. Mol. Life Sci. 64, 345-355 (2007)
19. Garcia-Horsman, J. A. et al. Deficient activity of mammalian prolyl oligopeptidase on the immunoactive peptide digestion in coeliac disease. Scand. J. Gastroenterol. 42, 562-571 (2007)
20. Mitea, C. et al. Efficient degradation of gluten by a prolyl endoprotease in a gastrointestinal model: implications for coeliac disease. Gut 57, 25-32 (2008)
21. Shan, L., Marti, T., Sollid, L. M., Gray, G. M. & Khosla, C. Comparative biochemical analysis of three bacterial prolyl endopeptidases: implications for coeliac sprue. Biochem. J. 383, 311-318 (2004)
22. Edens, L. et al. Extracellular prolyl endoprotease from Aspergillus niger and its use in the debittering of protein hydrolysates. J. Agric. Food Chem. 53, 7950-7957 (2005)
23. Marti, T. et al. Prolyl endopeptidase-mediated destruction of T cell epitopes in whole gluten: chemical and immunological characterization. J. Pharmacol. Exp. Ther. 312, 19-26 (2005)
24. Stepniak, D. et al. Highly efficient gluten degradation with a newly identified prolyl endoprotease: implications for celiac disease. Am. J. Physiol. Gastrointest. Liver Physiol. 291, G621-G629 (2006)
25. Pyle, G. G. et al. Effect of pretreatment of food gluten with prolyl endopeptidase on gluten-induced malabsorption in celiac sprue. Clin. Gastroenterol. Hepatol. 3, 687-694 (2005)
26. Bethune, M. T., Strop, P., Tang, Y., Sollid, L. M. & Khosla, C. Heterologous expression, purification, refolding, and structural-functional characterization of EP-B2, a self-Activating barley cysteine endoprotease. Chem. Biol. 13, 637-647 (2006)
27. Gass, J., Vora, H., Bethune, M. T., Gray, G. M. & Khosla, C. Effect of barley endoprotease EP-B2 on gluten digestion in the intact rat. J. Pharmacol. Exp. Ther. 318, 1178-1186 (2006)
28. Bethune, M. T. et al. A non-human primate model for gluten sensitivity. PLoS ONE 3, e1614 (2008)
29. Siegel, M. et al. Rational design of combination enzyme therapy for celiac sprue. Chem. Biol. 13, 649-658 (2006)
30. Gass, J., Bethune, M. T., Siegel, M., Spencer, A. & Khosla, C. Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue. Gastroenterology 133, 472-480 (2007)
31. Siegel, M. et al. Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials. Dig. Dis. Sci. 57, 440-450 (2012)
32. Tye-Din, J. A. et al. The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo. Clin. Immunol. 134, 289-295 (2010)
33. Lhdeaho, M.-L. et al. ALV003, a novel glutanase, attenuates gluten-induced small intestinal mucosal injury in coeliac disease patients: a randomized controlled phase 2a clinical trial. Gut Suppl. 60, A12 (2011)
34. Stenman, S. et al. Enzymatic detoxification of gluten by germinating wheat proteases: implications for new treatment of celiac disease. Ann. Med. 41, 390-400 (2009)
35. Stenman, S. et al. Degradation of coeliac disease-inducing rye secalin by germinating cereal enzymes: diminishing toxic effects in intestinal epithelial cells. Clin. Exp. Immunol. 161, 242-249 (2010)
36. Collado, M. C., Donat, E., Ribes-Koninckx, C., Calabuig, M. & Sanz, Y. Specific duodenal and faecal bacterial groups associated with paediatric coeliac disease. J. Clin. Pathol. 62, 264-269 (2009)
37. Wacklin, P. et al. The duodenal microbiota composition of adult celiac disease patients is associated to the clinical manifestation of the disease. Inflamm. Bowel Dis. 19, 934-941 (2013)
38. Lindfors, K. et al. Live probiotic Bifidobacterium lactis bacteria inhibit the toxic effects induced by wheat gliadin in epithelial cell culture. Clin. Exp. Immunol. 152, 552-558 (2008)
39. Laparra, J. M. & Sanz, Y. Bifidobacteria inhibit the inflammatory response induced by gliadins in intestinal epithelial cells via modifications of toxic peptide generation during digestion. J. Cell. Biochem. 109, 801-807 (2010)
40. Laparra, J. M., Olivares, M., Gallina, O. & Sanz, Y. Bifidobacterium longum CECT 7347 modulates immune responses in a gliadin-induced enteropathy animal model. PLoS ONE 7, e30744 (2012)
41. Smecuol, E. et al. Exploratory, randomized, double-blind, placebo-controlled study on the effects of Bifidobacterium infantis natren life start strain super strain in active celiac disease. J. Clin. Gastroenterol. 47, 139-147 (2013)
42. De Angelis, M. et al. VSL#3 probiotic preparation has the capacity to hydrolyze gliadin polypeptides responsible for celiac sprue. Biochim. Biophys. Acta 1762, 80-93 (2006)
43. Pinier, M. et al. Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium. Gastroenterology 136, 288-298 (2009)
44. Pinier, M. et al. The copolymer P(HEMA-co-SS) binds gluten and reduces immune response in gluten-sensitized mice and human tissues. Gastroenterology 142, 316-325 (2012)
45. Smecuol, E. et al. Gastrointestinal permeability in celiac disease. Gastroenterology 112, 1129-1136 (1997)
46. Ciccocioppo, R. et al. Altered expression, localization, and phosphorylation of epithelial junctional proteins in celiac disease. Am. J. Clin. Pathol. 125, 502-511 (2006)
47. Tripathi, A. et al. Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. Proc. Natl Acad. Sci. 106, 16799-16804 (2009)
48. Lammers, K. M. et al. Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology 135, 194-204 e193 (2008)
49. Di Pierro, M. et al. Zonula occludens toxin structure-function analysis. Identification of the fragment biologically active on tight junctions and of the zonulin receptor binding domain. J. Biol. Chem. 276, 19160-19165 (2001)
50. Clemente, M. G. et al. Early effects of gliadin on enterocyte intracellular signalling involved in intestinal barrier function. Gut 52, 218-223 (2003)
51. Drago, S. et al. Gliadin, zonulin and gut permeability: effects on celiac and non-celiac intestinal mucosa and intestinal cell lines. Scand. J. Gastroenterol. 41, 408-419 (2006)
52. Paterson, B. M., Lammers, K. M., Arrieta, M. C., Fasano, A. & Meddings, J. B. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment. Pharmacol. Ther. 26, 757-766 (2007)
53. Leffler, D. A. et al. A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge. Am. J. Gastroenterol. 107, 1554-1562 (2012)
54. Kelly, C. P. et al. Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. Aliment. Pharmacol. Ther. 37, 252-262 (2013)
55. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01396213 (2013)
56. Rauhavirta, T. et al. Epithelial transport and deamidation of gliadin peptides: a role for coeliac disease patient immunoglobulin A. Clin. Exp. Immunol. 164, 127-136 (2011)
57. Matysiak-Budnik, T. et al. Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease. J. Exp. Med. 205, 143-154 (2008)..
58. Mention, J. J. et al. Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology 125, 730-745 (2003)..
59. Maiuri, L. et al. IL-15 drives the specific migration of CD94+ and TCR-+ intraepithelial lymphocytes in organ cultures of treated celiac patients. Am. J. Gastroenterol. 96, 150-156 (2001)..
60. He, S. et al. A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 21, 367-377 (2004)
61. Ohta, N. et al. IL-15-dependent activation-induced cell death-resistant Th1 type CD8+NK1.1+ T cells for the development of small intestinal inflammation. J. Immunol. 169, 460-468 (2002)..
62. Maiuri, L. et al. Interleukin 15 mediates epithelial changes in celiac disease. Gastroenterology 119, 996-1006 (2000)
63. Sarra, M. et al. IL-15 positively regulates IL-21 production in celiac disease mucosa. Mucosal Immunol. 6, 244-255 (2013)
64. Malamut, G. et al. IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-Associated inflammation and lymphomagenesis. J. Clin. Invest. 120, 2131-2143 (2010)
65. Villanacci, V. et al. Mucosal tissue transglutaminase expression in celiac disease. J. Cell. Mol. Med. 13, 334-340 (2009)
66. Klock, C. & Khosla, C. Regulation of the activities of the mammalian transglutaminase family of enzymes. Protein Sci. 21, 1781-1791 (2012)
67. Dieterich, W. et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat. Med. 3, 797-801 (1997)
68. Molberg, O. et al. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat. Med. 4, 713-717 (1998)
69. Henderson, K. N. et al. A structural and immunological basis for the role of human leukocyte antigen DQ8 in celiac disease. Immunity 27, 23-34 (2007)
70. Siegel, M. & Khosla, C. Transglutaminase 2 inhibitors and their therapeutic role in disease states. Pharmacol. Ther. 115, 232-245 (2007)
71. Rauhavirta, T. et al. Are transglutaminase 2 inhibitors able to reduce gliadin-induced toxicity related to celiac disease? A proof-of-concept study. J. Clin. Immunol. 33, 134-142 (2013)
72. Molberg, O. et al. T cells from celiac disease lesions recognize gliadin epitopes deamidated in situ by endogenous tissue transglutaminase. Eur. J. Immunol. 31, 1317-1323 (2001)
73. Lebreton, C. et al. Interactions among secretory immunoglobulin A, CD71, and transglutaminase-2 affect permeability of intestinal epithelial cells to gliadin peptides. Gastroenterology 143, 698-707 (2012)
74. Xia, J. et al. Cyclic and dimeric gluten peptide analogues inhibiting DQ2-mediated antigen presentation in celiac disease. Bioorg. Med. Chem. 15, 6565-6573 (2007)
75. Kapoerchan, V. V. et al. Design of azidoproline containing gluten peptides to suppress CD4+ T-cell responses associated with celiac disease. Bioorg. Med. Chem. 16, 2053-2062 (2008)
76. Juse, U., van de Wal, Y., Koning, F., Sollid, L. M. & Fleckenstein, B. Design of new high-Affinity peptide ligands for human leukocyte antigen-DQ2 using a positional scanning peptide library. Hum. Immunol. 71, 475-481 (2010)
77. Huan, J. et al. Single-chain recombinant HLA-DQ2.5/peptide molecules block ?2-gliadin-specific pathogenic CD4+ T-cell proliferation and attenuate production of inflammatory cytokines: a potential therapy for celiac disease. Mucosal Immunol. 4, 112-120 (2011)
78. Sollid, L. M. & Khosla, C. Novel therapies for coeliac disease. J. Intern. Med. 269, 604-613 (2011)
79. Salvati, V. M. et al. Recombinant human interleukin 10 suppresses gliadin dependent T cell activation in ex vivo cultured coeliac intestinal mucosa. Gut 54, 46-53 (2005)
80. Mulder, C. J., Wahab, P. J., Meijer, J. W. & Metselaar, E. A pilot study of recombinant human interleukin-10 in adults with refractory coeliac disease. Eur. J. Gastroenterol. Hepatol. 13, 1183-1188 (2001)
81. Gillett, H. R. et al. Successful infliximab treatment for steroid-refractory celiac disease: a case report. Gastroenterology 122, 800-805 (2002)
82. Neurath, M. F. & Travis, S. P. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 61, 1619-1635 (2012)
83. Costantino, G. et al. Treatment of life-Threatening type I refractory coeliac disease with long-Term infliximab. Dig. Liver Dis. 40, 74-77 (2008)
84. Reinisch, W. et al. Fontolizumab in moderate to severe Crohns disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm. Bowel Dis. 16, 233-242 (2010)
85. Abraham, M. et al. In vitro induction of regulatory T cells by anti-CD3 antibody in humans. J. Autoimmun. 30, 21-28 (2008)
86. Hmida, N. B. et al. Impaired control of effector T cells by regulatory T cells: a clue to loss of oral tolerance and autoimmunity in celiac disease? Am. J. Gastroenterol. 107, 604-611 (2012)
87. Edwards, J. C. et al. Efficacy of B-cell-Targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350, 2572-2581 (2004)
88. Hauser, S. L. et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358, 676-688 (2008)
89. Lindfors, K., Mki, M. & Kaukinen, K. Transglutaminase 2-Targeted autoantibodies in celiac disease: pathogenetic players in addition to diagnostic tools? Autoimmun. Rev. 9, 744-749 (2010)
90. Mei, H. E. et al. Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab. Blood 116, 5181-5190 (2010)
91. Simon-Vecsei, Z. et al. A single conformational transglutaminase 2 epitope contributed by three domains is critical for celiac antibody binding and effects. Proc. Natl Acad. Sci. USA 109, 431-436 (2012)
92. Mora, J. R. & von Andrian, U. H. Differentiation and homing of IgA-secreting cells. Mucosal Immunol. 1, 96-109 (2008)
93. Olaussen, R. W. et al. Reduced chemokine receptor 9 on intraepithelial lymphocytes in celiac disease suggests persistent epithelial activation. Gastroenterology 132, 2371-2382 (2007)
94. Di Sabatino, A. et al. Increased expression of mucosal addressin cell adhesion molecule 1 in the duodenum of patients with active celiac disease is associated with depletion of integrin ?4?7-positive T cells in blood. Hum. Pathol. 40, 699-704 (2009)
95. Mora, J. R. Homing imprinting and immunomodulation in the gut: role of dendritic cells and retinoids. Inflamm. Bowel Dis. 14, 275-289 (2008)
96. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00540657 (2008)
97. Cassani, B. et al. Gut-Tropic T cells that express integrin ?4?7 and CCR9 are required for induction of oral immune tolerance in mice. Gastroenterology 141, 2109-2118 (2011)
98. Wermers, J. D., McNamee, E. N., Wurbel, M. A., Jedlicka, P. & Rivera-Nieves, J. The chemokine receptor CCR9 is required for the T-cell-mediated regulation of chronic ileitis in mice. Gastroenterology 140, 1526-1535 (2011)
99. Wurbel, M. A., McIntire, M. G., Dwyer, P. & Fiebiger, E. CCL25/CCR9 interactions regulate large intestinal inflammation in a murine model of acute colitis. PLoS ONE 6, e16442 (2011)
100. Tye-Din, J. A. et al. Comprehensive, quantitative mapping of T cell epitopes in gluten in celiac disease. Sci. Transl. Med. 2, 41ra51 (2010)
101. Daveson, A. J. et al. Effect of hookworm infection on wheat challenge in celiac disease-A randomised double-blinded placebo controlled trial. PLoS ONE 6, e17366 (2011)
102. Arentz-Hansen, H. et al. The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. J. Exp. Med. 191, 603-612 (2000)
103. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00879749 (2011)
104. Wigren, M. et al. Evidence for a role of regulatory T cells in mediating the atheroprotective effect of apolipoprotein B peptide vaccine. J. Intern. Med. 269, 546-556 (2011)
105. McSorley, H. J. et al. Suppression of inflammatory immune responses in celiac disease by experimental hookworm infection. PLoS ONE 6, e24092 (2011)
106. Croese, J., Gaze, S. T. & Loukas, A. Changed gluten immunity in celiac disease by Necator americanus provides new insights into autoimmunity. Int. J. Parasitol. 43, 275-282 (2013)